Stockwatch

Date	Sym	Type	Headline
2024-04-25 16:05	UU:PTCT	News Release200	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-04-23 16:30	UU:PTCT	News Release200	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-11 08:00	UU:PTCT	News Release200	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
2024-03-28 08:30	UU:PTCT	News Release200	PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
2024-03-19 07:30	UU:PTCT	News Release200	PTC Therapeutics Provides Key Regulatory Updates
2024-02-29 16:05	UU:PTCT	News Release200	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 17:20	UU:PTCT	News Release200	PTC Therapeutics to Participate at Upcoming Investor Conferences
2024-02-22 16:30	UU:PTCT	News Release200	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-15 08:00	UU:PTCT	News Release200	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
2024-01-25 16:05	UU:PTCT	News Release200	CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna ¢ „ ¢ (ataluren) Following Re-examination Procedure
2024-01-08 09:26	UU:PTCT	News Release200	PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 08:00	UU:PTCT	News Release200	PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-14 16:30	UU:PTCT	News Release200	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-05 16:15	UU:PTCT	News Release200	PTC Therapeutics Provides Updates on Translarna ¢ „ ¢ Regulatory Activities
2023-11-03 16:30	UU:PTCT	News Release200	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-26 16:05	UU:PTCT	News Release200	PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
2023-10-19 08:00	UU:PTCT	News Release200	PTC Therapeutics Announces Evrysdi ‚ ® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
2023-10-16 16:30	UU:PTCT	News Release200	PTC Therapeutics to Host Conference Call to Discuss ¢ € ¯Third Quarter 2023 Financial Results ¢ € ¯
2023-09-28 16:30	UU:PTCT	News Release200	PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
2023-09-15 06:00	UU:PTCT	News Release200	CHMP Delivers Opinion on Translarna ¢ „ ¢ for Conversion to Full Authorization
2023-09-12 08:00	UU:PTCT	News Release200	Sensorium Therapeutics Appoints Veteran Life Sciences Executive ‚ Mr. David Southwell to its Board of Directors
2023-09-07 08:00	UU:PTCT	News Release200	PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
2023-08-30 08:00	UU:PTCT	News Release200	PTC Therapeutics to Participate at Upcoming Investor Conferences
2023-08-28 08:00	UU:PTCT	News Release200	PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
2023-08-03 16:01	UU:PTCT	News Release200	PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
2023-07-21 09:30	UU:PTCT	News Release200	CHMP Recommends Evrysdi ‚ ® for Babies Under Two Months Old with Spinal Muscular Atrophy
2023-07-20 08:00	UU:PTCT	News Release200	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
2023-07-19 16:30	UU:PTCT	News Release200	PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
2023-07-18 16:30	UU:PTCT	News Release200	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-17 16:30	UU:PTCT	News Release200	PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
2023-07-11 12:00	UU:PTCT	News Release200	PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
2023-06-29 16:30	UU:PTCT	News Release200	PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
2023-06-21 07:00	UU:PTCT	News Release200	PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
2023-06-15 16:30	UU:PTCT	News Release200	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-02 08:00	UU:PTCT	News Release200	PTC Therapeutics to Participate at Upcoming Investor Conferences
2023-05-23 16:07	UU:PTCT	News Release200	PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
2023-05-23 16:05	UU:PTCT	News Release200	PTC Therapeutics Announces Strategic Pipeline Prioritization
2023-05-17 07:00	UU:PTCT	News Release200	PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients